The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 19, 2013
Filed:
Feb. 28, 2007
Daniel Obrecht, Baettwil, CH;
Frank Gombert, Binningen, CH;
Steven J. Demarco, Diegten, CH;
Christian Ludin, Oberwil, CH;
Jan Wim Vrijbloed, Moehlin, CH;
Kerstin Moehle, Wettswil, CH;
John-anthony Robinson, Wermatswil, CH;
Reshmi Mukherjee, Pasadena, CA (US);
Heiko Henze, Zurich, CH;
Barbara Romagnoli, Binningen, CH;
Daniel Obrecht, Baettwil, CH;
Frank Gombert, Binningen, CH;
Steven J. Demarco, Diegten, CH;
Christian Ludin, Oberwil, CH;
Jan Wim Vrijbloed, Moehlin, CH;
Kerstin Moehle, Wettswil, CH;
John-Anthony Robinson, Wermatswil, CH;
Reshmi Mukherjee, Pasadena, CA (US);
Heiko Henze, Zurich, CH;
Barbara Romagnoli, Binningen, CH;
Polyphor Ltd., Allschwil, CH;
Universitaet Zuerich, Zurich, CH;
Abstract
The template-fixed β-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala-Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immuno suppression; or for treating inflammation, or, in particular, for stem cell mobilization of peripheral blood stem cells and/or mesenchymal stem cell (MSC) and/or other stem cells which retention depend on the CXCR4-receptor.